Eckerström Carl, Olsson Erik, Klasson Niklas, Berge Josef, Nordlund Arto, Bjerke Maria, Wallin Anders
Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
J Alzheimers Dis. 2015;44(1):205-14. doi: 10.3233/JAD-141053.
Neuropsychological tests, CSF Aβ42, T-tau, P-tau181, hippocampal volume, and white matter lesions have been shown to predict conversion to dementia in patients with mild cognitive impairment (MCI).
To examine the predictive value of combinations of these markers and to examine if the absence of pathological markers provides a lasting reduction of conversion rates.
The Gothenburg MCI study is a clinically based study. Seventy-three MCI patients were included in the present sub-study and followed for a maximum of ten years. Thirty-four patients converted to dementia (18 to AD) and 39 remained stable. At inclusion, patients were classified into positive or negative risk groups according to results from neuropsychological testing (Rey auditory verbal learning test, Boston naming test, Trail making test B), CSF biomarkers (amyloid β42, T-tau, and P-tau181), and MRI scans (hippocampal volume, white matter lesions).
Trail making test B (TMT-B) was the best single predictor for the prediction of dementia (AUC 0.89, HR 25), and T-tau was the best predictor of AD (AUC 0.97, HR 41). The combination of hippocampal volume and TMT-B was the best combination for the prediction of dementia (HR 25), and the combination of hippocampal volume and T-tau was the best combination for the prediction of AD (HR 37).
Neuropsychological tests, CSF markers, and hippocampal volume predicted conversion from MCI to AD and general dementia. The absence of pathological markers provided a long-time protection from dementia.
神经心理学测试、脑脊液β淀粉样蛋白42(Aβ42)、总tau蛋白(T-tau)、磷酸化tau蛋白181(P-tau181)、海马体积和白质病变已被证明可预测轻度认知障碍(MCI)患者向痴呆的转化。
研究这些标志物组合的预测价值,并探讨缺乏病理标志物是否能持续降低转化率。
哥德堡MCI研究是一项基于临床的研究。本亚研究纳入了73例MCI患者,最长随访10年。34例患者转化为痴呆(18例为阿尔茨海默病(AD)),39例保持稳定。纳入时,根据神经心理学测试(雷伊听觉词语学习测验、波士顿命名测验、连线测验B)、脑脊液生物标志物(淀粉样蛋白β42、总tau蛋白和磷酸化tau蛋白181)以及磁共振成像扫描(海马体积、白质病变)的结果,将患者分为阳性或阴性风险组。
连线测验B(TMT-B)是预测痴呆的最佳单一指标(曲线下面积(AUC)为0.89,风险比(HR)为25),总tau蛋白是预测AD的最佳指标(AUC为0.97,HR为41)。海马体积和TMT-B的组合是预测痴呆的最佳组合(HR为25),海马体积和总tau蛋白的组合是预测AD的最佳组合(HR为37)。
神经心理学测试、脑脊液标志物和海马体积可预测MCI向AD及一般性痴呆的转化。缺乏病理标志物可长期预防痴呆。